fb-lrx
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 16, 2018 (NCT03446144)
Timeline
Indications
Mechanism of action
- Complement factor BANTISENSE INHIBITOR
CFB antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05797610 | Phase 3 | Aug 8, 2023 | Roche |
| NCT04014335 | Phase 2 | Aug 31, 2019 | Ionis Pharmaceuticals, Inc. |
| NCT03815825 | Phase 2 | Mar 4, 2019 | Ionis Pharmaceuticals, Inc. |
| NCT03446144 | Phase 2 | Mar 16, 2018 | Ionis Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 3 | 3 | 1 | 2018 |
| Roche | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1